Author

S. C. Sivakumaren

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Assay:metabolomics· 1

Frequent Co-Authors

N. S. Gray· 2 shared A. Jenney· 1 shared A. Palmer· 1 shared B. Jiang· 1 shared C. M. Browne· 1 shared C. Mills· 1 shared C. Yapp· 1 shared D. G. Wang· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

N. S. Gray

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivOct 25, 2019

Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors

S. C. Sivakumaren, H. Shim, T. Zhang…·N. S. Gray

This study identifies THZ-P1-2, a covalent pan-PI5P4K inhibitor, showing efficacy in AML/ALL cell lines and autophagy disruption, supporting PI5P4Ks as therapeutic targets in cancer.

DOI 10.1016/j.chembiol.2020.02.003

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 12, 2019

Combined inhibition of mTOR and PIKKs exploits replicative and checkpoint vulnerabilities to induce death of PI3K-activated triple-negative breast cancer cells

S. S. Chopra, A. Jenney, A. Palmer…·P. K. Sorger

The paper shows that combining mTOR and PIKK inhibitors kills triple-negative breast cancer cells by exploiting replication and checkpoint vulnerabilities.

DOI 10.1101/700625

humanproteomics

𝕏 PostBluesky